BHRT Compounded Overview: Estradiol Oral, Patch, Gel, and Spray Compared

What Is BHRT and How Does It Differ from Conventional HRT?

Bioidentical hormone replacement therapy uses hormones whose molecular structure matches the hormones the human body makes. Estradiol (17-beta-estradiol) is the primary estrogen used in both conventional HRT and BHRT. The key distinction is not the molecule but the source and regulatory status of the product: FDA-approved formulations go through Phase III trials proving safety, efficacy, and manufacturing consistency, while compounded BHRT is mixed by a compounding pharmacy for an individual prescription and bypasses that review process.

The Endocrine Society's 2016 Scientific Statement noted that "compounded bioidentical hormones pose more risk than FDA-approved bioidentical hormones," citing variable potency and the absence of large randomized controlled trial data for compounded preparations. [1] That does not mean compounded products are never appropriate. Women with documented allergies to excipients in commercial products, or who need doses that do not exist in any FDA-approved formulation, may have a legitimate clinical reason for compounded therapy. Outside those narrow indications, FDA-approved bioidentical estradiol products (Climara, Vivelle-Dot, Divigel, Estrace, Evamist) deliver the same molecule with verified dosing accuracy.

Progesterone co-therapy is mandatory for any woman with an intact uterus receiving systemic estrogen. Unopposed estrogen raises the relative risk of endometrial cancer by approximately 2- to 12-fold depending on duration of use. [2] FDA-approved oral micronized progesterone (Prometrium 100 mg or 200 mg) is bioidentical to endogenous progesterone and is the preferred agent in most NAMS-aligned prescribing.

Oral Estradiol: Convenient but with Specific Metabolic Trade-Offs

Oral estradiol is the simplest form to prescribe and the easiest for patients to take. A daily pill requires no application technique, and generic 1 mg tablets cost under $20 per month at most pharmacies.

The pharmacological trade-off is first-pass hepatic metabolism. Swallowed estradiol passes through the liver before reaching systemic circulation, which raises sex hormone-binding globulin (SHBG), triglycerides, and C-reactive protein (CRP) to a measurable degree. [3] The clinical consequence that matters most: the Estrogen and Thromboembolism Risk (ESTHER) case-control study (N=881) found that oral estrogen users had roughly a 4-fold higher venous thromboembolism (VTE) risk compared to non-users, while transdermal users showed no statistically significant increase. [4] Women with personal or first-degree family history of VTE, hypertriglyceridemia, or known thrombophilia should be steered away from oral estradiol toward a transdermal route.

Standard starting doses are 0.5 mg to 1 mg daily, titrated up to 2 mg daily based on symptom response at 6-8 weeks. Doses above 2 mg are not FDA-approved and would require compounding. Most women with moderate-to-severe vasomotor symptoms respond adequately within the approved range.

Estradiol Patches: Steady-State Delivery with Twice-Weekly Convenience

Transdermal patches deliver estradiol directly through the skin, bypassing hepatic first-pass metabolism entirely. Serum estradiol levels stay relatively stable between patch changes, which some women find reduces symptom breakthrough compared to daily oral dosing.

Two patch schedules exist. Matrix patches (Climara, Menostar) are changed once weekly. Reservoir patches (Vivelle-Dot, Alora) are changed twice weekly. Vivelle-Dot 0.05 mg per day is among the most commonly prescribed, with a delivery rate equivalent to roughly 50 mcg of estradiol per 24 hours. [5]

The ESTHER study data cited above, along with the Nurses' Health Study follow-up analyses, consistently show no significant VTE elevation with transdermal estradiol at doses of 0.05 mg per day or below. [4] This safety profile makes patches the preferred option for women who are overweight, older, or have mild cardiovascular risk factors. Skin adhesion can be a practical issue, particularly in humid climates. Rotating application sites (abdomen, buttock, lower back) and pressing firmly for 30 seconds after application improves adhesion. Some women develop local erythema under the patch; switching brands often resolves this because adhesive formulations differ.

The approved dose range is 0.025 mg to 0.1 mg per day. Women requiring more than 0.1 mg per day are outside the labeled range and should be reassessed for whether the dose is genuinely necessary.

Estradiol Gel (Divigel): Flexible Dosing with a Quick Dry Time

Divigel 0.1% estradiol gel comes in single-use foil packets dosed at 0.25 g, 0.5 g, 0.75 g, 1.0 g, and 1.5 g, providing approximately 0.25 mg to 1.5 mg of estradiol per application. The gel is applied once daily to one thigh, alternating sides, and dries within two to three minutes.

A Phase III trial supporting Divigel's FDA approval (N=495) demonstrated that 0.25 g per day reduced the frequency of moderate-to-severe hot flashes by 73% from baseline at 12 weeks, compared to 51% for placebo. [6] The 1.0 g dose reduced hot-flash frequency by 77%. All doses statistically outperformed placebo (P<0.001).

Gel has one practical risk that patches and pills do not: accidental transfer. Estradiol can rub off onto a partner or child through skin contact before the gel dries. The FDA label for Divigel specifically instructs patients to keep the application site covered with clothing and to avoid direct skin contact with others until the gel has fully dried. [7] Women who share a bed with children or who are highly physically affectionate with a partner immediately after application may prefer a patch, which eliminates transfer risk once applied.

Other commercially available estradiol gels include EstroGel (0.06%), which is pumped rather than packeted and delivers 0.75 mg per pump actuation. Compounded estradiol gels exist at various concentrations but lack the dose-delivery verification that FDA-approved products carry.

Estradiol Spray (Evamist): Fast Application, Dose Stacking Option

Evamist is a metered-dose transdermal spray delivering 1.53 mg of estradiol per spray to the inner forearm. The starting dose is one spray daily, with titration to two or three sprays if symptoms persist at the four-week reassessment.

The Phase III Evamist trial (N=454) showed that three sprays daily reduced moderate-to-severe hot-flash frequency by 57.5% at 12 weeks versus 33.1% for placebo (P<0.001). [8] The spray dries in under 60 seconds for most patients and leaves no residue. Like gel, it carries an accidental-transfer warning; the FDA label instructs patients to wash hands immediately after application and to cover the site with clothing.

One clinical advantage of the spray format: dose adjustments feel more intuitive to patients because adding one spray is a concrete, countable action. Women who find it hard to remember how many grams of gel they applied often adapt more reliably to a spray count. The three-spray maximum maps to approximately 4.59 mg of nominal estradiol delivered topically, though actual systemic absorption is substantially lower due to skin uptake variability.

Compounded BHRT: When It Makes Sense and When It Does Not

Compounded BHRT sits in a regulatory gray area. The FDA does not approve compounded preparations, but licensed compounding pharmacies operating under 503A or 503B designations can prepare individualized prescriptions. The legitimate use cases are narrow.

A reasonable clinical framework for compounded estradiol looks like this:

Tier 1: FDA-approved products are almost always the right first choice. A woman with no documented contraindication to commercial excipients who wants 0.5 mg, 1 mg, or 2 mg oral estradiol, or a standard-dose patch, gel, or spray, has multiple FDA-approved options. Compounding is not justified on the basis of cost alone in most cases, because generic estradiol tablets are inexpensive and Vivelle-Dot is widely available on GoodRx for under $40 per month.

Tier 2: Compounding may be appropriate for specific, documented clinical needs. A patient with a confirmed allergy to a patch adhesive component (e.g., acrylic), or who needs 1.5 mg oral estradiol (not a standard commercial tablet), or who needs a combined estradiol plus estriol cream for vaginal atrophy refractory to commercial vaginal estradiol (Vagifem, Imvexxy, Estrace vaginal), may have a genuine indication. The prescribing clinician should document the rationale clearly.

Tier 3: Salivary hormone testing to guide compounded BHRT dosing is not supported by evidence. The Endocrine Society explicitly states that salivary estradiol levels do not reliably correlate with tissue levels or symptom burden. [1] Serum estradiol measured at trough (before the next dose) is the appropriate monitoring lab.

The NAMS 2022 Position Statement states: "Compounded hormone therapy should not be considered equivalent to FDA-approved hormone therapy, and it should not be used without compelling individualized clinical rationale." [9]

Choosing Between Formulations: A Practical Comparison

No single delivery method is best for every woman. The decision involves clot risk, lifestyle, skin sensitivity, partner and child contact, cost, and personal preference. The table below organizes the key variables.

Oral estradiol works well for women with no VTE risk factors, no hypertriglyceridemia, and who prefer the simplicity of a daily pill. The cost barrier is lowest.

Transdermal patches are preferred for women with elevated BMI (BMI >30), prior VTE risk factors, hypertriglyceridemia, or migraine with aura. Twice-weekly dosing suits women who find daily application inconvenient.

Divigel or EstroGel suits women who prefer topical application over a visible adhesive patch but who do not have young children or close physical contact with others immediately post-application.

Evamist spray suits women who want precise, incremental dose titration in a fast-drying format and who can commit to consistent forearm application site management.

A 2019 analysis published in Menopause (N=39,070 women from the Danish nationwide cohort) found that transdermal estradiol carried a significantly lower VTE hazard ratio (HR 0.99 to 95% CI 0.79-1.24) compared to oral estradiol (HR 1.40 to 95% CI 1.22-1.61). [10] The absolute risk difference remains small in healthy women under 60, but it justifies choosing transdermal when clinical factors are otherwise equal.

Safety, Monitoring, and Duration of Use

The Women's Health Initiative (WHI) 2002 publication alarmed clinicians and patients by reporting increased breast cancer and cardiovascular risk with combined conjugated equine estrogen plus medroxyprogesterone acetate. Later reanalysis showed that the elevated risk was concentrated in women who were older (mean age 63), had more cardiovascular risk factors, and were more than 10 years past menopause onset. [11]

NAMS, the British Menopause Society, and the International Menopause Society all now endorse hormone therapy for symptomatic women under 60 or within 10 years of menopause onset who have no contraindications, specifically noting that the benefit-risk ratio is favorable in this population. [9] Women who begin HRT in their 50s and use it for 5-7 years face a breast cancer absolute risk increase roughly equivalent to drinking one glass of wine per night, according to the Collaborative Group on Hormonal Factors in Breast Cancer (2019, N=108,647). [12]

Monitoring after initiation should include a serum estradiol level at 6-8 weeks (target trough 40-100 pg/mL for most symptomatic women), blood pressure, and a symptom review. Annual well-woman exams with mammography per age-appropriate guidelines continue regardless of HRT status. There is no fixed maximum duration; therapy should be reassessed annually with the patient using a shared decision-making framework.

The Role of Progesterone in BHRT Regimens

Every woman with a uterus who takes systemic estrogen needs progestogen coverage. The choice of progestogen matters.

Medroxyprogesterone acetate (MPA), the synthetic progestogen used in the WHI trial, appears to attenuate some cardiovascular benefits of estradiol and may contribute to the modest breast cancer signal. [11] Oral micronized progesterone (OMP, Prometrium) is bioidentical to luteal-phase progesterone and shows a more favorable cardiovascular and breast tissue profile in observational data. The E3N cohort study (N=80,377) found that women using estradiol plus OMP had no statistically significant increase in breast cancer risk over 8.1 years of follow-up, compared to a significant increase with estradiol plus synthetic progestogens. [13]

Standard dosing is Prometrium 100 mg nightly for women using continuous combined regimens, or 200 mg nightly for 12-14 days per month for sequential regimens. Women who have had a hysterectomy do not need progestogen unless they choose to use progesterone for other reasons (some data suggests sleep and mood benefits from OMP at 100 mg nightly). [14]

How Compounded Estriol Fits In

Estriol (E3) is a weaker endogenous estrogen primarily produced during pregnancy. It is not FDA-approved as a systemic menopause therapy in the United States, but it appears frequently in compounded BHRT preparations, sometimes combined with estradiol in a product called "bi-est" (typically 80% estriol / 20% estradiol by proportion).

Evidence for systemic estriol reducing hot flashes is limited. A Cochrane review on estriol found that vaginal estriol effectively treats genitourinary syndrome of menopause (GSM) with minimal systemic absorption, but data on systemic bi-est preparations for vasomotor symptoms are sparse and do not meet the evidentiary bar set by FDA-approved therapies. [15] Vaginal estriol cream (compounded at 0.5 mg per gram) is a reasonable option for women with GSM who cannot tolerate or afford FDA-approved vaginal estradiol products.

Serum Monitoring Targets by Formulation

Serum estradiol targets vary by route because absorption efficiency differs. Oral estradiol produces higher SHBG due to first-pass effects, which means serum total estradiol may read higher than tissue-available estradiol.

For transdermal routes, a trough serum estradiol of 40-100 pg/mL correlates with adequate vasomotor symptom relief in most women, based on data from the Vivelle-Dot Phase III program. [5] For oral estradiol, trough levels should be interpreted alongside symptom response; a level of 60-120 pg/mL at trough is typical on 1 mg daily. Labs drawn more than 24 hours after the last oral dose underestimate steady-state levels and should not be used to guide dose increases.

Women using compounded preparations should be monitored with the same serum targets, recognizing that dose delivery from compounded products may be less predictable. If a patient is symptomatic at a serum estradiol level that should be therapeutic, the first step is confirming that they are applying or taking the medication consistently and correctly, before assuming the compounded dose is inadequate.